SJTRI has been awarded the following grants:

$60,080 from Juvenile Diabetes Research Foundation International
New Combined Encapsulant with T Cell Repellent to Sustain Islet Transplants. This study is a collaborative effort between Massachusetts General Hospital (Harvard Medical School), Georgia Institute of Technology, and Saint Joseph’s Translational Research Institute. The project aims to research a novel method to utilize T cell repellent as a means of overcoming rejection that combines maintenance of long term islet viability with establishment of immune isolation for the engrafted tissue without the need for immune suppressive drug therapy.

$332,958 from the National Institutes of Health – Grand Opportunities
Mechanisms of Race-Based Differences in Factor VIII Immunogenicity in Hemophilia. The treatment of bleeding episodes in patients with Hemophilia A consists of transfusions of Factor VIII (FVIII), the protein whose activity is deficient in these patients. However, an immune response in the form of neutralizing antibodies may complicate the therapy. Through joint efforts with Sepulveda Research Corporation and Saint Joseph’s Translational Research Institute, this project will characterize the antibodies and study the genetic influences of this reaction.

Jaipal Singh, Ph.D., has joined SJTRI as Chief Scientific Officer.  Dr. Singh was most recently with Eli Lilly and Company, where he served as head of vascular therapeutics research and research advisor for the Atherosclerosis-Metabolic drug hunting team. Read More.